From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: KMK

Search articles by EPIC code
EPIC KMK
views

Kromek – “Award of £5m bio-threat contract by UK Government”, but how are those overall financials?

Describing itself as “a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments”, Kromek Group (KMK) has announced “Award of £5m bio-threat contract by UK Government”. It emphasises that it is “delighted to have been awarded this contract… Governments throughout the world are reviewing their strategies to update their defence against such threats. We believe technologies that can provide information about emerging threats in near real time will be a critical component of such strategies”, but what of a share price currently above 9p in response, approaching 12% higher?

EPIC KMK
views

Kromek – further fundraising, how are the financials?

Previously writing on group which describes itself as “a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments” Kromek (KMK), last month I noted a new distribution agreement but asked what about financials?, and concluded continue to avoid. Now it “is pleased to announce that it has completed a fundraising of £1.14 million through the issue of convertible loan notes”.

EPIC KMK
views

Kromek – is “foreseeable future” this time longer than three and a half months?...

Previously writing on group now describing itself as “a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments” Kromek (KMK), in July with the shares down towards 15p I reviewed “well-placed to capitalise on the substantial opportunities”, concluding still a sell. It today provides an update, with its year ended 30th April.

Page 1 of 3 (22 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments